Search Clinical Trials
Sponsor Condition of Interest |
---|
COVID-19 In-vitro Diagnostic Test and Androgen Receptor Gene Expression
University of California, Irvine
Covid19
Androgen Receptor Gene Overexpression
This research study will evaluate the association of Androgen Receptor (AR) gene
expression and COVID-19 disease severity and mortality. The research procedure involves
collection of a single saliva sample which will be mailed to the participants by the
study team. This saliva will be used in a COVID-19... expand
This research study will evaluate the association of Androgen Receptor (AR) gene expression and COVID-19 disease severity and mortality. The research procedure involves collection of a single saliva sample which will be mailed to the participants by the study team. This saliva will be used in a COVID-19 Androgen Sensitivity Test (CoVAST) which will detect AR gene expression. Eligible participants are males, at least 18 years or older, and have tested positive for COVID-19. Type: Observational Start Date: Aug 2020 |
Predictors of Severe COVID-19 Outcomes
Verily Life Sciences LLC
Acute Respiratory Distress Syndrome
COVID-19
This is a longitudinal, multi-center, observational study collecting diverse biological
measurements and clinical and epidemiological data for the purpose of enabling a greater
understanding of the onset of severe outcomes, primarily acute respiratory distress
syndrome (ARDS) and/or mortality, in... expand
This is a longitudinal, multi-center, observational study collecting diverse biological measurements and clinical and epidemiological data for the purpose of enabling a greater understanding of the onset of severe outcomes, primarily acute respiratory distress syndrome (ARDS) and/or mortality, in patients presenting to the hospital with suspicion or diagnosis of COVID-19. We seek to understand whether there are early signatures that predict progression to ARDS, mortality, and/or other comorbid conditions. The duration of the study participation is approximately 3 months. Type: Observational Start Date: May 2020 |
Understanding Community Considerations, Opinions, Values, Impacts, and Decisions for COVID-19
University of California, Los Angeles
Covid-19
Critical Illness
Attitude of Health Personnel
Attitude to Health
Health Behavior
The novel coronavirus (COVID-19) is affecting the way many people live their lives,
including seeking medical care and maintaining good self-care to keep healthy.
Additionally, in the event many people become critically ill at once, COVID-19 has the
possibility of overwhelming hospitals to the point... expand
The novel coronavirus (COVID-19) is affecting the way many people live their lives, including seeking medical care and maintaining good self-care to keep healthy. Additionally, in the event many people become critically ill at once, COVID-19 has the possibility of overwhelming hospitals to the point where they have to make decisions about how to determine who receives intensive care and life-support measures. Many hospitals as well as local or state governments have been working on policies to determine how to make these decisions. This study seeks to learn about how COVID-19 has affected the way patients and healthcare providers care for themselves and about their thoughts and concerns about policies that may "ration" life-support resources. Type: Interventional Start Date: May 2020 |
Duke COVID-19 Shared Data and Specimen Repository
Duke University
COVID-19
The purpose of this data repository is to provide a secure and centralized storage
location and resource for the collection of essential data and medical specimens, across
COVID-19 related protocols at Duke. expand
The purpose of this data repository is to provide a secure and centralized storage location and resource for the collection of essential data and medical specimens, across COVID-19 related protocols at Duke. Type: Observational [Patient Registry] Start Date: Apr 2020 |
COVID-19 PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY)
University of California, San Francisco
Pregnancy
Coronavirus
COVID-19
PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY) is a prospective cohort study of
pregnant and recently pregnant women who are: either patients under investigation for
COVID-19 or a confirmed case of COVID-19. Data from PRIORITY will be used to evaluate the
impact of COVID-19 on the clinical course... expand
PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY) is a prospective cohort study of pregnant and recently pregnant women who are: either patients under investigation for COVID-19 or a confirmed case of COVID-19. Data from PRIORITY will be used to evaluate the impact of COVID-19 on the clinical course and pregnancy outcomes of pregnant women and women within 6 weeks of pregnancy. Type: Observational [Patient Registry] Start Date: Mar 2020 |
Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus...
Basilea Pharmaceutica
Invasive Fungal Infections
This is a Phase 2, multicenter study to evaluate APX001 for the treatment of invasive
fungal infections caused by Aspergillus spp. or rare molds (eg, Scedosporium spp.,
Fusarium spp., and Mucorales fungi). expand
This is a Phase 2, multicenter study to evaluate APX001 for the treatment of invasive fungal infections caused by Aspergillus spp. or rare molds (eg, Scedosporium spp., Fusarium spp., and Mucorales fungi). Type: Interventional Start Date: Jan 2020 |
Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel
Abbott Rapid Dx
COVID-19
Influenza A
Influenza B
The study is designed as a prospective, multicentric, clinical study to investigate the
positive percent agreement (PPA) and negative percent agreement (NPA) of the Panbio™
COVID-19/Flu A&B Panel using anterior nasal swab specimens tested directly, relative to
the comparator methods, Roche cobas®... expand
The study is designed as a prospective, multicentric, clinical study to investigate the positive percent agreement (PPA) and negative percent agreement (NPA) of the Panbio™ COVID-19/Flu A&B Panel using anterior nasal swab specimens tested directly, relative to the comparator methods, Roche cobas® SARS-CoV-2 (K231306) and Quidel Lyra® Influenza A+B Assay(K230236) (RT-PCR) in symptomatic patients suspected of respiratory viral infection by a healthcare provider. Type: Interventional Start Date: Nov 2023 |
Building Engagement Using Financial Incentives Trial - Colorectal Cancer Screening
Tulane University
Health Behavior
Colorectal Cancer
Influenza
COVID-19
Vaccine Hesitancy
The goal of this pilot clinical trial is to determine feasibility and explore whether
financial incentives paid to primary care patients for completing colorectal cancer
screening increase completion of colorectal cancer screening. The main questions it aims
to answer are:
- Do patient financial... expand
The goal of this pilot clinical trial is to determine feasibility and explore whether financial incentives paid to primary care patients for completing colorectal cancer screening increase completion of colorectal cancer screening. The main questions it aims to answer are: - Do patient financial incentives for completing colorectal cancer screening increase screening completion? - Does a patient financial incentive for colorectal cancer screening offered alongside patient financial incentives for COVID-19 and flu shots increase completion of those shots? Participants who are due for colorectal cancer screening will receive telephone outreach from primary care staff who will offer a stool-based colorectal cancer screening. Participants will be randomly assigned to either Group 1 or Group 2. Group 1 participants will be offered financial incentives for completing COVID-19 and flu shots within 2 months of enrollment. Group 2 participants will be offered financial incentives for completing a COVID-19 shot, a flu shot, and colorectal cancer screening within 2 months of enrollment. Researchers will compare to see if completion of a COVID-19 shot, a flu shot, and colorectal cancer screening is different between the two groups. Type: Interventional Start Date: Nov 2023 |
COVID Booster in Pregnancy and Lactation
Thomas Jefferson University
COVID-19
This is a prospective longitudinal cohort study to evaluate the impact of COVID-19
vaccination and booster on maternal and infant immunity against COVID-19 variants over
time. expand
This is a prospective longitudinal cohort study to evaluate the impact of COVID-19 vaccination and booster on maternal and infant immunity against COVID-19 variants over time. Type: Observational Start Date: Sep 2022 |
COVID-19 & Psychiatry: A Retrospective Chart Review
Northwestern University
COVID-19
A retrospective chart review study to determine the effects of psychotropic medications
and prior psychiatric diagnoses on COVID-19 patients' disease progression, and severity. expand
A retrospective chart review study to determine the effects of psychotropic medications and prior psychiatric diagnoses on COVID-19 patients' disease progression, and severity. Type: Observational Start Date: Jan 2022 |
A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study.
Sean Liu
SARS-CoV-2
This study will be a phase-1, open-label, placebo-controlled, evaluation of two-dosages
of a live, recombinant Newcastle disease virus expressing the spike protein of SARS-CoV-2
(NDV-HXP-S), an investigational product for IN, IM, or a combined IN+IM vaccination in
healthy adults previously immunized... expand
This study will be a phase-1, open-label, placebo-controlled, evaluation of two-dosages of a live, recombinant Newcastle disease virus expressing the spike protein of SARS-CoV-2 (NDV-HXP-S), an investigational product for IN, IM, or a combined IN+IM vaccination in healthy adults previously immunized against COVID-19. The IN and IM live virus vaccinations will be identical in composition and only differ in route of administration. Type: Interventional Start Date: Feb 2022 |
Safety and Acceptability of Q GRFT Nasal Spray for COVID-19 Prophylaxis
Sharon Hillier
COVID-19
Pharmacokinetics
Safety
This is a phase I randomized, placebo-controlled, single site to assess the local and
systemic safety of intranasal Q-Griffithsin (Q-GRFT) after 14 doses in approximately 45
adult participants. Participants will be randomized 2:1 (Q-GRFT nasal spray: placebo
nasal spray) resulting in 30 participants... expand
This is a phase I randomized, placebo-controlled, single site to assess the local and systemic safety of intranasal Q-Griffithsin (Q-GRFT) after 14 doses in approximately 45 adult participants. Participants will be randomized 2:1 (Q-GRFT nasal spray: placebo nasal spray) resulting in 30 participants enrolled into the Q-GRFT arm and 15 participants enrolled into the placebo arm. A clinician will apply two metered doses of Q-GRFT in each nostril (400μl total) of the participant on the day of enrollment. Participants will be monitored in the clinic for 1 hour after administration and return for a 24-hour post dose visit. If safe and acceptable, a second period of daily administration by the participant for 13 days will commence. Safety assessments will be performed at day 7, day 14, and day 28 visits after the initiation of the second period. The expected duration of study participation for each participant will be approximately 6-8 weeks. The primary endpoint is the proportion of participants who experience a related Grade 2 or higher adverse event. Secondary and exploratory endpoints include persistence and systemic absorption of Q-GRFT, acceptability and the impact of Q-GRFT nasal spray on smell. Type: Interventional Start Date: Mar 2022 |
COVID-19 (Coronavirus Disease-2019) Psychiatric Outcomes
Weill Medical College of Cornell University
Covid19
Anxiety
Mood
Cognitive Impairment
The goal of this longitudinal and observational study is to better understand the
psychiatric consequences of COVID-19 over time. Psychiatric outcomes like mood, anxiety,
stress, and cognitive symptoms in patients who underwent inpatient hospitalization at
NewYork-Presbyterian Hospital/Weill Cornell... expand
The goal of this longitudinal and observational study is to better understand the psychiatric consequences of COVID-19 over time. Psychiatric outcomes like mood, anxiety, stress, and cognitive symptoms in patients who underwent inpatient hospitalization at NewYork-Presbyterian Hospital/Weill Cornell Medicine for COVID-19 will be assessed at 6 months or later post-discharge. Type: Observational Start Date: Dec 2021 |
Text Message Nudges for COVID-19 Vaccination
Mitesh Patel
Covid19
The COVID-19 pandemic has caused significant morbidity and mortality across the world.
Effective vaccines are now available but underutilized. In July 2021, Ascension Health
implemented a mandate requiring all employees to obtain the COVID-19 vaccine by November
12th. In August 2021, the number of... expand
The COVID-19 pandemic has caused significant morbidity and mortality across the world. Effective vaccines are now available but underutilized. In July 2021, Ascension Health implemented a mandate requiring all employees to obtain the COVID-19 vaccine by November 12th. In August 2021, the number of COVID-19 cases in the US increased rapidly, specifically in states with lower vaccination rates, many of which are served by Ascension Health facilities. In this study, we will evaluate a rapidly deployed health system initiative to use text messaging to nudge Ascension employees who have not yet been vaccinated to commit to a date and receive vaccination. Type: Interventional Start Date: Oct 2021 |
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
National Institute of Allergy and Infectious Diseases (NIAID)
Rheumatoid Arthritis (RA)
Systemic Lupus Erythematosus (SLE)
Pemphigus Vulgaris
Multiple Sclerosis (MS)
Systemic Sclerosis (SSc)
This is a randomized, multi-site, adaptive, open-label clinical trial comparing the
immune response to different additional doses of COVID-19 vaccine in participants with
autoimmune disease requiring IS medications. All study participants will have negative
serologic or suboptimal responses (defined... expand
This is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different additional doses of COVID-19 vaccine in participants with autoimmune disease requiring IS medications. All study participants will have negative serologic or suboptimal responses (defined as a Roche Elecsys® Anti-SARS-CoV-2 S result ≤200 U/mL) or a low immune response (defined as a Roche Elecsys® Anti-SARS-CoV-2 S result >200 U/ml and ≤2500 U/mL) to their previous doses of COVID-19 vaccine. The study will focus on 5 autoimmune diseases in adults: - Systemic Lupus Erythematosus (SLE) - Rheumatoid Arthritis (RA) - Multiple Sclerosis (MS) - Systemic Sclerosis (SSc), and - Pemphigus. This study will focus on 4 autoimmune diseases in pediatric participants: - Systemic Lupus Erythematosus (SLE) - Juvenile Idiopathic Arthritis (JIA) - Pediatric-Onset Multiple Sclerosis (POMS) - Juvenile Dermatomyositis (JDM) Type: Interventional Start Date: Aug 2021 |
COVID-19 Recovery Study: Symptoms and Biomarkers of Long COVID-19 in People Living With and Without HIV
Johns Hopkins University
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2)
HIV
This observational study will prospectively characterize the long-term symptoms and side
effects of COVID-19 in cohorts of people living with and without HIV. This will be
achieved through a series of remote study visits involving completing surveys about
health history, symptoms, mood, quality of... expand
This observational study will prospectively characterize the long-term symptoms and side effects of COVID-19 in cohorts of people living with and without HIV. This will be achieved through a series of remote study visits involving completing surveys about health history, symptoms, mood, quality of life and changes in health, and up to two blood draws from home through the use of a mobile phlebotomy service. Type: Observational Start Date: Jun 2021 |
Community Network-driven COVID-19 Testing and Vaccination of Vulnerable Populations in the Central US
University of Chicago
Covid19
This C3 project, Community network-driven COVID-19 testing of vulnerable populations in
the Central US, will implement and evaluate a COVID-19 testing and vaccination approach
that combines an evidence-based Social Network Testing Strategy (SNS) with community
developed COVID-19 public health messages... expand
This C3 project, Community network-driven COVID-19 testing of vulnerable populations in the Central US, will implement and evaluate a COVID-19 testing and vaccination approach that combines an evidence-based Social Network Testing Strategy (SNS) with community developed COVID-19 public health messages (SNS+). C3 will engage two disenfranchised populations across rural and urban sites in states across the Central US (Texas (TX), Louisiana (LA), Arkansas (AR), Indiana (IN), Illinois (IL)). C3 leverages NIDA's Justice Community Opioid Innovation Network (JCOIN), the PIs' extensive community located COVID-19 testing programs, and a network of established community partnerships. The collaborative community-academic partnerships, research and engagement infrastructure, and team's leadership across JCOIN will ensure that C3 can rapidly recruit, enroll and test most disenfranchised community members, (n=2400) and through this process, accelerate any forthcoming COVID-19 public health prevention interventions. C3 focuses on two communities most impacted by COVID-19: 1) Criminal justice involved (CJI) - non-incarcerated people with previous history of arrest/jail/prison, probation/parole, drug-court attendance, witnessed or experienced a negative interaction with police or law enforcement; and 2) Low-income Latinx - community members at 250% or below Federal Poverty Level. Both of these diverse populations, and the overlap between them, have some of the highest rates of COVID-19 infection and death in the United States. Messaging that affirms individual agency and corrects misinformation, combined with accessible and acceptable testing, is required to accelerate COVID-19 prevention for these populations.Using a two-arm randomized controlled trial design, participants will be enrolled into the Social Network testing Strategy (SNS) arm (involves social networking referrals only) or the Social Network testing Strategy with COVID-19 prevention messages (SNS+) messaging arm. The latter includes affirmation/misinformation correction messaging (discussion tools and coaching). SNS and SNS+messaging arms will both include an initial group of index study participants who will refer their network members into the study and the process will repeat itself one more time for a total of 3 waves. Indexes will refer network members (1st degree) and then those network members will refer one more round (2nd degree). Type: Interventional Start Date: Apr 2021 |
Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19
VA Office of Research and Development
Coronavirus Disease 2019 (COVID-19)
The purpose of this study is to assess whether convalescent plasma therapy is associated
with reduced 30-day all-cause mortality in a population of Veteran inpatients with
non-severe coronavirus disease 2019 (COVID-19). expand
The purpose of this study is to assess whether convalescent plasma therapy is associated with reduced 30-day all-cause mortality in a population of Veteran inpatients with non-severe coronavirus disease 2019 (COVID-19). Type: Observational Start Date: May 2020 |
Early Extubation for Patients With Acute Hypoxemic Respiratory Failure
University of Chicago
Mechanical Ventilation
Corona Virus Infection
The objective of the study is to evaluate the efficacy of helmet NIV in reducing the
duration of invasive mechanical ventilation in order to minimize ventilator needs during
the COVID-19 pandemic. expand
The objective of the study is to evaluate the efficacy of helmet NIV in reducing the duration of invasive mechanical ventilation in order to minimize ventilator needs during the COVID-19 pandemic. Type: Interventional Start Date: Aug 2020 |
A Prospective "Universal" Observational Database for COVID-19
Hackensack Meridian Health
COVID-19
The Hackensack Meridian Health Universal Observational COVID-19, a descriptive
observational database, is a multi-center initiative collecting data throughout the
Hackensack Meridian Health Network (HMH). HMH utilizes the EPIC system at most of the
facilities, which will serve as the primary data... expand
The Hackensack Meridian Health Universal Observational COVID-19, a descriptive observational database, is a multi-center initiative collecting data throughout the Hackensack Meridian Health Network (HMH). HMH utilizes the EPIC system at most of the facilities, which will serve as the primary data source. The database will be designed within the REDCap system. A de-identified dataset will be sent to COTA for primary statistical analysis as requested by the research teams. Type: Observational [Patient Registry] Start Date: Mar 2020 |
Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection
Washington University School of Medicine
Coronavirus Infection
This Phase III trial four treatment strategies non-critically ill hospitalized
participants (not requiring intensive care unit (ICU) admission and/or mechanical
ventilation) with SARS CoV-2 infection, Participants will receive hydroxychloroquine or
chloroquine with or without azithromycin. expand
This Phase III trial four treatment strategies non-critically ill hospitalized participants (not requiring intensive care unit (ICU) admission and/or mechanical ventilation) with SARS CoV-2 infection, Participants will receive hydroxychloroquine or chloroquine with or without azithromycin. Type: Interventional Start Date: Apr 2020 |
Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia
University of Cincinnati
COVID-19
The main objective of our study is to determine if treatment with sirolimus can improve
clinical outcomes in hospitalized patients with COVID-19. The investigators will employ a
randomized, double blind, placebo-controlled study design. 28 subjects were randomized in
a 2:1 fashion to receive sirolimus... expand
The main objective of our study is to determine if treatment with sirolimus can improve clinical outcomes in hospitalized patients with COVID-19. The investigators will employ a randomized, double blind, placebo-controlled study design. 28 subjects were randomized in a 2:1 fashion to receive sirolimus or placebo. Sirolimus will be given as a 6mg oral loading dose on day 1 followed by 2mg daily for a maximum treatment duration of 14 days or until hospital discharge, whichever happens sooner. Chart reviews will be conducted daily to determine changes in clinical status, concomitant medications and laboratory parameters. Study specific biomarkers will be measured at baseline and then at days 3, 7 and 14. Type: Interventional Start Date: Apr 2020 |
Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection
Shionogi
SARS-CoV-2 Infection
The purpose of this study is to measure the proportion of participants who are infected
with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (positive reverse
transcription polymerase chain reaction [RT-PCR] test) and have coronavirus disease 2019
(COVID-19) symptom(s) with S-217622 tablets... expand
The purpose of this study is to measure the proportion of participants who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (positive reverse transcription polymerase chain reaction [RT-PCR] test) and have coronavirus disease 2019 (COVID-19) symptom(s) with S-217622 tablets compared with placebo tablets in participants who are household contacts of an individual with symptomatic COVID-19. Type: Interventional Start Date: Jun 2023 |
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
University of Texas Southwestern Medical Center
SARS-CoV Infection
COVID-19
Adults who do not have major health, kidney, gastrointestinal disease will be randomized
to receive oral mitoquinone/mitoquinol mesylate (Mito-MES) versus placebo to prevent the
development and progression of COVID-19 after high-risk exposure to a person with
confirmed SARS-CoV-2 infection. expand
Adults who do not have major health, kidney, gastrointestinal disease will be randomized to receive oral mitoquinone/mitoquinol mesylate (Mito-MES) versus placebo to prevent the development and progression of COVID-19 after high-risk exposure to a person with confirmed SARS-CoV-2 infection. Type: Interventional Start Date: Mar 2024 |
The COPE Study: Pilot Intervention to Improve Symptom Self-management and Coping in Adults With Post...
University of Washington
Post COVID-19 Condition
Post-COVID-19 Syndrome
This project is a randomized controlled pilot trial using mixed methods to examine the
feasibility, acceptability, and initial effects of a telemedicine group-based
intervention designed to improve symptom management and coping in adults with Post-COVID. expand
This project is a randomized controlled pilot trial using mixed methods to examine the feasibility, acceptability, and initial effects of a telemedicine group-based intervention designed to improve symptom management and coping in adults with Post-COVID. Type: Interventional Start Date: Jan 2023 |
- Previous
- Next